top of page

CSO presented at CTGTAC

The Cellular, Tissue and Gene Therapies Advisory Committee held a virtual public meeting meeting on 2-3rd September on the toxicity risks of AAV gene therapy. TestAVec CSO, Prof. Michael Themis presented evidence during the Open Public Hearing session. This was a thoroughly stimulating discussion and shows the present need to understand these vectors and integration related side effects in greater detail. Use the YouTube link below to view both Day 1 and Day 2 sessions.




Commentaires


bottom of page